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Abstract
Introduction:  The first and foremost rule in the treatment of superficial bladder cancer is correct and complete
resection of the tumor. Histopathological analysis of the resected tumor will help to define the correct tumor
stage, thus delaying or, ideally, avoiding tumor recurrence and progression.
Objectives:  To examine the prognostic factors for residual tumors in the tumor base or in another area of
the bladder in patients subjected to repeat transurethral resection (re-TUR).
Patients  and  methods: Between September 2009 and August 2014, 188/221 patients advised to undergo
re-TUR for stage T1 tumors were subjected to the procedure. The following data were collected for this
retrospective study: patients’ age and sex, information on whether initial TUR was carried out for a primary
tumor/primary tumors, tumor number, tumor size and tumor grade, as well as information on whether
muscularis propria was found in the resected specimens of initial TUR, whether there was carcinoma in situ
and whether single-dose intracavitary chemotherapy was administered following initial TUR.
Results: On re-TUR, new tumors outside of the previous resection area were found in 34 (18%) and residual
tumors in the initial resection area in 48 (25.5%) patients. 61.7% of the patients diagnosed with new tumors
outside of the previous tumor area and 62.5% of those with residual tumors in the initial resection area
had initially undergone TUR for multifocal tumors. Both univariate and multivariate analysis revealed a
n male sex, multifocal primary tumors and the detection of residual tumors
uring re-TUR.significant relationship betwee
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Conclusion:  For the reasons mentioned above, we believe that re-TUR will influence the treatment strategies
and have an impact on T1-tumor progression, especially with regard to multifocal tumors.
© 2016 Pan African Urological Surgeons’ Association. Production and hosting by Elsevier B.V. All rights reserved.
I
T
i
i
c
o
a
s
(
s
a
r
t
[
m
b
f
a
t
r
P
I
w
a
o
g
t
s
h
T
1
I
c
w
s
h
w
T
c
w
c
T
t
D
a
t
F
a
f
t
w
w
c
S
r
r
R
1
6
3
1
w
8
C
i
s
O
o
w
w
h
a
r
i
i
B
r
d
r
d
p
t
w
D
7
b
7
N
antroduction
he gold standard in the diagnosis and treatment of bladder cancer
s transurethral resection (TUR). The first and the foremost rule
n the treatment of superficial bladder cancer is the correct and
omplete resection of the tumor [1,2]. Histopathological analysis
f the resected tumor will help to correctly define the tumor stage,
nd therefore delay and even avoid tumor recurrence and progres-
ion. Guidelines published by the European Association of Urology
EAU 2014) suggest repeat TUR (re-TUR) in all high-grade T1 and
elected high-grade Ta tumors [3–5]. During re-TUR, microscopic
nd/or macroscopic residual tumors can be identified in the initial
esection area or new areas. For the detection of residual tumors,
he grade, stage, size and number of the initial tumor(s) is important
4–7]. It is known that residual tumors diagnosed during re-TUR
ay be due to technical insufficiency or to the fact that they have
een overlooked during initial TUR [5,8–12]. Another important
actor is the grade of tumor invasion [5,8–12]. In this study, we
imed to examine the prognostic factors for residual tumor detec-
ion in the tumor base or in another area in patients subjected to
e-TUR.
atients  and  methods
n this retrospective study, we reviewed the data of 1021 patients
ho underwent TUR for superficial bladder tumors between 2009
nd 2014. As a routine practice in our clinic we perform a sec-
nd TUR in patients with T1 tumors, regardless of the pathological
rade, multiplicity or recurrence factor. 221 patients were advised
o have re-TUR for T1 tumors. Of these, 18 refused re-TUR, 8 were
ubjected to radical cystectomy due to widespread tumors, 3 had a
igh anesthesia risk and 4 were lost to follow-up after initial TUR.
hus, 33 patients were excluded from the study, leaving a total of
88 patients subjected to re-TUR.
nitial TUR was done using standard 30◦ and 70◦ optic lenses for
ystoscopy. Using a hot loop, all the visible tumors were excised
ith either en-bloc or graded resection, depending on the tumor
ize. The resected tumors as well as the tumor bases were sent for
istopathological assessment. Patients with T1 pathology results
ere scheduled for re-TUR within a 4–6 week period from initial
UR. 96 patients scheduled for re-TUR received single-dose intra-
avitary chemotherapy following the initial operation. 92 patients
ith postoperative hematuria were not eligible for single-dose intra-
avitary chemotherapy. The patients were called 2 weeks after initial
UR to review their histopathological results and to discuss further
reatment which was planned according to the pathology results.uring re-TUR, all visible tumors were resected. Afterwards, the
reas of initial TUR were also resected and sent in different con-
ainers for histopathological analysis.
S
f
oor statistical analysis, the following data were collected: patients’
ge and sex, information on whether initial TUR was carried out
or a primary tumor/primary tumors, tumor number, tumor size and
umor grade, as well as information on whether muscularis propria
as found in the resected specimens of initial TUR, whether there
as carcinoma in situ (CIS) and whether single-dose intracavitary
hemotherapy was administered following initial TUR.
PSS 20.0 for Windows was used for statistical analysis. The logistic
egression analysis and chi-square analysis were used for the data
eview.
esults
68 male and 20 female patients aged between 31 and 78 (mean
7.3) years received re-TUR. 157 (83.5%) patients had primary and
1 (16.5%) had recurrent tumors. Initial TUR was performed on
06 (56.3%) patients with a single tumor and 82 (43.7%) patients
ith multifocal tumors. 106 (56.3%) patients had high-grade and
2 (43.7%) low-grade T1 tumors. In 20 (10.6%) patients, additional
IS was detected. 96 (51%) patients received single-dose intracav-
tary chemotherapy, while 92 (49%) patients were not eligible for
ingle-dose intracavitary chemotherapy due to hematuria.
n re-TUR, 34 (18%) patients were diagnosed with new tumors
utside of the resection area, while 48 (25.5%) had residual tumors
ithin the initial resection area. In 61.7% of the patients diagnosed
ith residual tumors outside of the initial resection area, initial TUR
ad been performed for multifocal tumors (Table 1). The tumor stage
nd grade were found to be increased in 5 (2%) and 6 (3%) patients,
espectively. Radical cystectomy was performed on the patients with
ncreased tumor stage. The other patients were treated with BCG
mmunotherapy.
oth univariate and multivariate analysis revealed a significant
elationship between male sex, multifocal primary tumors and the
etection of residual tumors in the previous resection area during
e-TUR. (Table 2) (p  < 0.05). A new tumor in a new area detected
uring re-TUR was found to be significantly related to multifocal
rimary tumors only (Table 3) (p  < 0.0001). No morbidity or mor-
ality was seen in the patients subjected to re-TUR in connection
ith this procedure.
iscussion
0–75% of newly diagnosed bladder tumors are non-muscle invasive
ladder tumors (NMIBC). About 1–10% of those tumors are CIS,
0–80% of them are Ta and 20% of them are T1 tumors [13–15].
MIBC type tumors are a heterogeneous disease group and cover
 wide range in terms of recurrence, progression and survival rates.
tage pT1 tumors are usually high-grade tumors with a high risk
or progression [16,17]. Those tumors tend to progress in 29–74%
f the patients over a 5-year period [18]. The shift of superficial
Factors that predict residual tumors in re-TUR patients 
Table  1  Patient characteristics.
N (%)
Sex
Male 168 (89.3%)
Female 20 (10.7%)
Primary tumor + 157 (83.5%)− 31 (16.5%)
Grade
Low 82 (43.7%)
High 106 (56.3%)
Tumor size
<3 cm 111 (59%)
>3 cm 77 (41%)
Tumor number
Solitary 106 (56.3%)
Multifocal 82 (43.7%)
Concomitant CIS
+ 20 (10.6%)
− 168 (89.3%)
Tumor stage (re-TUR)
T0 140 (74.4%)
Ta 9 (4.7%)
T1 33 (17.5%)
T2 5 (2.6%)
CIS 1 (0.5%)
Histopathological
stage/grade (re-TUR)
High grade 6 (3.1%)
T2 5 (2.6%)
CIS 1 (0.5%)
Total 12 (6.3%)
CIS: carcinoma in situ.
Table  2  Residual tumors detected on re-TUR.
Variant Univariate
(p score)
Multivariate
(p score)
Sex (M/F) 0.003 0.004
Primary/recurrent Tumor 0.933
Solitary/multifocal Tumor 0.005 0.006
Tumor size (<3 cm/ > 3 cm) 0.498
Tumor grade (low/high) 0.886
Presence of muscularis propria (+/−) 0.188
Presence of CIS (+/−) 0.064
Single-dose chemotherapy (+/−) 0.585
CIS: carcinoma in situ.
Bold values indicate that P values <0.05 were considered to be statisti-
cally significant.
Table  3  Newly diagnosed tumors detected on re-TUR.
Variant Univariate
(p score)
Multivariate
(p score)
Sex (M/F) 0.098
Primary/recurrent Tumor 0.856
Solitary/multifocal Tumor 0.001
Tumor size (<3 cm/ > 3 cm) 0.652
Tumor grade (low/high) 0.521
Presence of muscularis propria (+/−) 0.213
Presence of CIS (+/−) 0.078
Single-dose chemotherapy(+/−) 0.645
CIS: carcinoma in situ.
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TBold values indicate that P values <0.05 were considered to be statisti-
cally significant.
tumors to muscle invasive tumors with time is reported to show a
worse prognosis in comparison with initial muscle invasive tumor
diagnosis [19]. This shows the importance of primary treatment in
non-muscle invasive tumors [20].
s
e
f69
ecurrence is detected during the first control cystoscopy in
0–81.5% of patients with superficial bladder tumors [21]. Whether
his is due to insufficient resection or new tumor growth is still ques-
ionable. Tumor detection during the first control cystoscopy gives
mportant clues about the prognosis of the disease and is accepted
s a negative prognostic factor [22,23]. Especially in multiple and
nvasive tumors, single TUR is thought to be insufficient to com-
letely remove the diseased tissue and may cause early recurrences
nd stage progression against the additional intravesical treatments
5,24].
esidual tumors in the initial resection area or in a new area can
e seen microscopically or macroscopically during re-TUR. Stage,
rade, number and size of the initial tumor(s) affect the detection of
esidual tumors [4–7,25–29]. One of the first studies in this subject
as carried out by Klan et al. on 46 patients with stage pT1 disease.
ven though the surgeon’s reports showed complete tumor resection
n TUR, 20 of 40 patients subjected to re-TUR were diagnosed with
esidual tumors [30]. Another important study performed by Herr
t al. stresses the importance of re-TUR, as their results showed
esidual tumors in 76% and stage progression in 28% of their patients
11]. The first prospective study on this subject was done by Grimm
t al. in 2003 [4]. In their study, they report on the long-term follow-
p results of 83 patients (63 with stage Ta and 20 with stage T1
ancer) who underwent re-TUR. Residual tumors were seen in 33%,
hile low staging was seen in 8% of their patients. Residual tumors
ere found in the area of initial tumor resection in 46% and in a new
rea in 19% of the patients. Univariate analysis revealed a significant
elationship between residual tumor detection and stage and grade
f the initial tumor [4].
nother study reviewing the efficacy of re-TUR and residual tumor
redictive factors was done by Schwaibold et al. [7]. In this study,
36 patients with stage pT1 tumors who had initially been subjected
o standard TUR and underwent re-TUR were reviewed. 71(23%) of
hem were diagnosed with residual tumors during re-TUR. Stage or
rade progression was seen in 28 (21%) patients. Residual tumors
n the initial resection area were seen in 86% and in another area
n 14% of the patients. The presence of residual tumors was found
o be significantly related to multiple initial tumors, yet it was not
elated to tumor size or grade.
n the present study, we found a similar incidence of residual tumors
etected on re-TUR. In accordance with other studies published
n the literature, we found that multifocal tumors were an impor-
ant factor leading to the risk of residual tumors after initial TUR.
e believe that the reason for the increased occurrence of residual
umors in patients with multifocal tumors may be due to factors that
bstruct the view during the intervention, such as bleeding, which
ncreases the operation time and renders resection in all tumor areas
ore difficult.
he presence of residual tumors in patients with concomitant CIS
as not found to be statistically significant in our study, but a close
alue. This can be explained with the low number of patients. Thus,
oncomitant CIS may also be a factor predictive of residual tumors.
he results of our study and the other studies found in the literature
how a higher occurrence of residual tumors in stage-T1 tumor dis-
ase which highlights the importance of re-TUR as well as the need
or more careful resection of multifocal tumors.
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[0 
he observation in our study that more residual tumors were found
n male compared to female patients may be attributed to the low
umber of female patients in our study.
he limited number of patients and the retrospective study type are
he limitations of our study. We believe, however, that studies on a
arger number of patients will support our results.
onclusion
he fact that stage-T1 tumors have a larger tumor load than pre-
iously assumed has been supported by the results of our study
nd other studies in the literature. This can be seen more clearly in
atients with multifocal tumors. For the reasons mentioned above,
e believe that re-TUR will influence the treatment strategies and
ave an impact on T1-tumor progression, especially with regard to
ultifocal tumors.
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